<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00508664</url>
  </required_header>
  <id_info>
    <org_study_id>TP(F)+Radiation+/-Cetuximab</org_study_id>
    <nct_id>NCT00508664</nct_id>
  </id_info>
  <brief_title>Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)</brief_title>
  <acronym>DeLOS II</acronym>
  <official_title>Randomised Phase II Screening Study to be Used in an TP/TPF-chemotherapy (Short Induction) Before TP/TPF-induction, Radiotherapy With or Without Cetuximab in the Primary Therapy of the Only by Laryngectomy Operable Carcinoma of the Larynx/Hypopharynx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ClinAssess</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DeLOS II trial is a multicenter randomised phase II trial investigating a
      TP/5-Fluorouracil (TPF)-chemotherapy with or without cetuximab for Patients with only by
      laryngectomy operable carcinoma of the larynx/hypopharynx. Patients were divided in responder
      or non-responder after 4 weeks. Since August 2009 Responder receive TP with or without
      Cetuximab + radiation. (Until february 2009 Responder received TPF with or without Cetuximab
      + radiation.) Planned accrual is 85 patients per treatment arm. The primary study endpoint is
      a confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2
      years after randomisation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2 years after randomisation</measure>
    <time_frame>LFS-rate 2 years after randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of the study arms concerning the secondary end criteria of the study</measure>
    <time_frame>LSF 2 years after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explorative comparison of the study arms concerning the primary and secondary end criteria of the study</measure>
    <time_frame>LSF 2 years after randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Larynx Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TP + Radiation (TPF until Feb 2009)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TP + Cetuximab + Radiation (TPF until Feb 2009)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Radiation start in week 11</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2 i.v. day 1 3 times</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (TP)</intervention_name>
    <description>75 mg/m2 i.v. day 1 3 times</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil (TPF) (only until Feb 2009)</intervention_name>
    <description>Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed, primary only with laryngectomy respectable squamous-cell
             carcinoma of the larynx or hypopharynx

          -  T3-T4a carcinoma of the glottis

          -  T2-T4a carcinoma of the supraglottic, only controllable by laryngectomy and if
             applicable by root of tongue segmental resection

          -  T2-T4a carcinoma of the hypopharynx only controllable by laryngectomy (for example T2,
             post cricoidal) and hypopharynx segmental resection

          -  N-status: cervical metastases (N0-N3) have to be rehabilitate by surgical procedures

               -  Blood count: Leukocytes &gt;3500/mm\3, Neutrophils &gt; 1500/ mm\3, Thrombocytes &gt;
                  8000/ mm\3

               -  Clinical chemistry:

          -  adequate renal function, defined by serum creatinine and urea not higher than 25%
             upper NL, creatinine-clearance &gt; 60 ml/min/1,72 m\2

          -  adequate hepatic function with SGOT, SGPT not higher than 50% and bilirubin not higher
             than upper NL

          -  electrolytes at NL

               -  anesthetic risk normal or low-grade elevated

               -  age 18-75 years

               -  written informed consent

               -  effective contraception after individual advice for men and women if there is a
                  possibility of reproductive potential (effective contraception are: oral
                  contraception with estrogen and gestagen (no minipill), vaginal ring,
                  contraception patch, estrogen free ovulation suppressors, hormone spiral with
                  progesterone, injection for three month with depot gestagen, hormone releasing
                  implantation (luteal hormone containing rod), abstinence or sterilization
                  (vasectomy) of the male)

        Exclusion Criteria:

          -  primary cancer treatable by operational larynx -conserving procedures

          -  distant metastases (M1-Status)

          -  total tumor volume exceeding 80 ml or larynx skeleton punctuated with infiltration of
             surrounding soft tissues respectively the esophageal aditus (exclusive cartilage
             infiltration represents no exclusion criteria)

          -  tumor-specific prior chemo or radiotherapy

          -  metachronous or synchronous malignant tumor (exception basalioma) [in case of a
             controlled tumor of different localization with a non-treated interval over 5 years to
             the present therapy the patient can be included after consultation with the
             coordinating investigator]

          -  life expectancy &lt; 3 month

          -  Karnofsky performance status &lt; 70%

          -  serious cardiopulmonary concomitant disease (cardiac insufficiency grade III and IV
             according NYHA status, myocardial infarction, angina pectoris, respiratory global
             insufficiency)

          -  Chronic diseases with permanent-therapy (uncontrolled diabetes, active rheumatoid
             arthritis)

          -  recurrent pneumonia, COPD GOLD stage &lt;2, chronic inflammation of intestine or any
             other concomitant diseases, which disallow study participation in the opinion of the
             responsible physician

          -  Other circumstances (contra-indications), which disallow treatment with Docetaxel,
             Cisplatin, 5-FU, Cetuximab or radiotherapy

          -  Expected absent patient compliance

          -  Periodic follow-up not possible (for example address outside germany)

          -  Pregnant or breast-feeding woman

          -  Absent or constricted legal capacity

          -  Participation to another clinical trial with any investigational study within 30 days
             prior to study screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Dietz, Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik für HNO</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Klagenfurt</name>
      <address>
        <city>Klagenfurt</city>
        <zip>A-9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt GmbH Klinik für HNO-Heilkunde, Plastische Operationen</name>
      <address>
        <city>Erfurt</city>
        <state>Thüringen</state>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Neukölln, Vivantes GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld-Mitte</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Anna gGmbH, HNO-Klinik</name>
      <address>
        <city>Duisburg</city>
        <zip>47259</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda gAG, Klinik für Hals-Nasen-Ohrenkrankheiten</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Hannover Nordstadt</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Kliniken</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel GmbH</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Koblenz Marienhof</name>
      <address>
        <city>Koblenz</city>
        <zip>56073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät der Westfälischen Wilhelms-Universität Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Südharz-Krankenhaus Nordhausen gGmbH</name>
      <address>
        <city>Nordhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann gGmbH</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart Katharinenhospital, Klinik für HNO-Krankheiten</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayerischen Julius Maximillians-Universtät Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2007</study_first_submitted>
  <study_first_submitted_qc>July 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2007</study_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>ClinAssess</investigator_full_name>
    <investigator_title>Prof. Dietz, Universität Leipzig</investigator_title>
  </responsible_party>
  <keyword>by laryngectomy operable carcinoma of the larynx and the hypopharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

